Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission - Archive ouverte HAL Access content directly
Journal Articles American Journal of Hematology Year : 2018

Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission

, , , , , , , , , , , , (1, 2) , , , , , ,
1
2
Francesca Lorentino
  • Function : Author
Myriam Labopin
Massimo Bernardi
  • Function : Author
Fabio Ciceri
Gerard Socie
  • Function : Author
Jan J. Cornelissen
  • Function : Author
Jordi Esteve
Annalisa Ruggeri
Liisa Volin
  • Function : Author
Ibrahim Yacoub-Agha
  • Function : Author
Charles Craddock
  • Function : Author
Jacob Passweg
  • Function : Author
Tobias Gedde-Dahl
  • Function : Author
Monica Poiani
  • Function : Author
Nathalie Fegueux
  • Function : Author
Mohamad Mohty
Arnon Nagler
European Soc Blood Marrow
  • Function : Author

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) is the most powerful therapy preventing relapse in patients with adverse cytogenetics acute myeloid leukemia (AML) in first complete remission (CR1). In the absence of a matched related donor, potential alternatives include 10/10, 9/10 HLA-matched unrelated (UD) or haploidentical (Haplo) donors. We analyzed clinical outcomes of patients undergoing T-cell repleted Haplo (n =74), 10/10 UD (n =433) and 9/10 UD HSCT (n =123) from 2007 to 2015, reported to the EBMT Registry. Adverse risk AML was defined according to the 2017 ELN cytogenetic risk classification. The 2-year nonrelapse mortality was 19% for Haplo, 18% for 10/10 UD and 18% for 9/10 UD (P =.9). The relapse incidence was not significantly affected by donor source, with a 2-year incidence of 27% for Haplo HSCT, 39% for 10/10 UD and 37% for 9/10 UD SCT (P =.3). We show comparable probabilities of leukemia-free survival (LFS) and overall survival (OS) at 2 years among Haplo HSCT, 10/10 UD SCT and 9/10 UD SCT (53% and 59%, 43% and 50%, 44% and 50%, respectively, P =.5 for both parameters). The type of donor was not significantly associated with either acute or chronic graft-vs.-host disease incidence. Using multivariable Cox model, Haplo HSCT recipients experienced comparable OS and LFS to 10/10 and 9/10 UD. In the present series of adverse cytogenetics AML patients in CR1, Haplo HSCT recipients had comparable outcomes to those of 10/10 and 9/10 UDs, suggesting that all these types of HSCT may be considered a valid option in this high risk population.

Dates and versions

hal-02143598 , version 1 (29-05-2019)

Identifiers

Cite

Francesca Lorentino, Myriam Labopin, Massimo Bernardi, Fabio Ciceri, Gerard Socie, et al.. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. American Journal of Hematology, 2018, 93 (10), pp.1236-1244. ⟨10.1002/ajh.25231⟩. ⟨hal-02143598⟩

Collections

CNRS UNIV-AMU CRCM
19 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More